Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 53


HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human melanoma model.

Schrörs B, Lübcke S, Lennerz V, Fatho M, Bicker A, Wölfel C, Derigs P, Hankeln T, Schadendorf D, Paschen A, Wölfel T.

Oncotarget. 2017 Apr 25;8(17):28312-28327. doi: 10.18632/oncotarget.16048.


An optimized IFN-γ ELISpot assay for the sensitive and standardized monitoring of CMV protein-reactive effector cells of cell-mediated immunity.

Barabas S, Spindler T, Kiener R, Tonar C, Lugner T, Batzilla J, Bendfeldt H, Rascle A, Asbach B, Wagner R, Deml L.

BMC Immunol. 2017 Mar 7;18(1):14. doi: 10.1186/s12865-017-0195-y.


mRNA-transfected dendritic cell vaccine in combination with metronomic cyclophosphamide as treatment for patients with advanced malignant melanoma.

Borch TH, Engell-Noerregaard L, Zeeberg Iversen T, Ellebaek E, Met Ö, Hansen M, Andersen MH, Thor Straten P, Svane IM.

Oncoimmunology. 2016 Jul 8;5(9):e1207842. eCollection 2016.


Validation of an IFNγ/IL2 FluoroSpot assay for clinical trial monitoring.

Körber N, Behrends U, Hapfelmeier A, Protzer U, Bauer T.

J Transl Med. 2016 Jun 14;14(1):175. doi: 10.1186/s12967-016-0932-7.


Phase Ib study of poly-epitope peptide vaccination to thymidylate synthase (TSPP) and GOLFIG chemo-immunotherapy for treatment of metastatic colorectal cancer patients.

Correale P, Botta C, Martino EC, Ulivieri C, Battaglia G, Carfagno T, Rossetti MG, Fioravanti A, Guidelli GM, Cheleschi S, Gandolfo C, Carbone F, Baldari TC, Tassone P, Tagliaferri P, Pirtoli L, Cusi MG.

Oncoimmunology. 2015 Dec 21;5(4):e1101205. eCollection 2016 Apr.


Variability of the IFN-γ ELISpot assay in the context of proficiency testing and bridging studies.

Rountree W, Berrong M, Sanchez AM, Denny TN, Ferrari G.

J Immunol Methods. 2016 Jun;433:69-76. doi: 10.1016/j.jim.2016.03.004. Epub 2016 Mar 25.


Pooled-Peptide Epitope Mapping Strategies Are Efficient and Highly Sensitive: An Evaluation of Methods for Identifying Human T Cell Epitope Specificities in Large-Scale HIV Vaccine Efficacy Trials.

Fiore-Gartland A, Manso BA, Friedrich DP, Gabriel EE, Finak G, Moodie Z, Hertz T, De Rosa SC, Frahm N, Gilbert PB, McElrath MJ.

PLoS One. 2016 Feb 10;11(2):e0147812. doi: 10.1371/journal.pone.0147812. eCollection 2016.


An HLA-Transgenic Mouse Model of Type 1 Diabetes That Incorporates the Reduced but Not Abolished Thymic Insulin Expression Seen in Patients.

Babad J, Ali R, Schloss J, DiLorenzo TP.

J Diabetes Res. 2016;2016:7959060. doi: 10.1155/2016/7959060. Epub 2015 Dec 28.


A Simple Proteomics-Based Approach to Identification of Immunodominant Antigens from a Complex Pathogen: Application to the CD4 T Cell Response against Human Herpesvirus 6B.

Becerra-Artiles A, Dominguez-Amorocho O, Stern LJ, Calvo-Calle JM.

PLoS One. 2015 Nov 23;10(11):e0142871. doi: 10.1371/journal.pone.0142871. eCollection 2015.


Multiplex Identification of Antigen-Specific T Cell Receptors Using a Combination of Immune Assays and Immune Receptor Sequencing.

Klinger M, Pepin F, Wilkins J, Asbury T, Wittkop T, Zheng J, Moorhead M, Faham M.

PLoS One. 2015 Oct 28;10(10):e0141561. doi: 10.1371/journal.pone.0141561. eCollection 2015.


Epitope specific T-cell responses against influenza A in a healthy population.

Savic M, Dembinski JL, Kim Y, Tunheim G, Cox RJ, Oftung F, Peters B, Mjaaland S.

Immunology. 2016 Feb;147(2):165-77. doi: 10.1111/imm.12548. Epub 2015 Dec 8.


A phase 1 study of a heterologous prime-boost vaccination involving a truncated HER2 sequence in patients with HER2-expressing breast cancer.

Kim SB, Ahn JH, Kim J, Jung KH.

Mol Ther Methods Clin Dev. 2015 Sep 30;2:15031. doi: 10.1038/mtm.2015.31. eCollection 2015.


Systems Biology Approach for Cancer Vaccine Development and Evaluation.

Circelli L, Petrizzo A, Tagliamonte M, Tornesello ML, Buonaguro FM, Buonaguro L.

Vaccines (Basel). 2015 Jul 14;3(3):544-55. doi: 10.3390/vaccines3030544. Review.


Chimpanzee adenovirus- and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults.

Green CA, Scarselli E, Sande CJ, Thompson AJ, de Lara CM, Taylor KS, Haworth K, Del Sorbo M, Angus B, Siani L, Di Marco S, Traboni C, Folgori A, Colloca S, Capone S, Vitelli A, Cortese R, Klenerman P, Nicosia A, Pollard AJ.

Sci Transl Med. 2015 Aug 12;7(300):300ra126. doi: 10.1126/scitranslmed.aac5745.


Study of the BCG Vaccine-Induced Cellular Immune Response in Schoolchildren in Antananarivo, Madagascar.

Ranaivomanana P, Raharimanga V, Dubois PM, Richard V, Rasolofo Razanamparany V.

PLoS One. 2015 Jul 27;10(7):e0127590. doi: 10.1371/journal.pone.0127590. eCollection 2015.


Immune monitoring technology primer: the enzyme-linked immunospot (Elispot) and Fluorospot assay.

Janetzki S.

J Immunother Cancer. 2015 Jul 21;3:30. doi: 10.1186/s40425-015-0074-0. eCollection 2015. No abstract available.


Improvement of IFNg ELISPOT Performance Following Overnight Resting of Frozen PBMC Samples Confirmed Through Rigorous Statistical Analysis.

Santos R, Buying A, Sabri N, Yu J, Gringeri A, Bender J, Janetzki S, Pinilla C, Judkowski VA.

Cells. 2014 Dec 24;4(1):1-18. doi: 10.3390/cells4010001. Erratum in: Cells. 2015;4(2):133-4.


Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer.

Sebastian M, Papachristofilou A, Weiss C, Früh M, Cathomas R, Hilbe W, Wehler T, Rippin G, Koch SD, Scheel B, Fotin-Mleczek M, Heidenreich R, Kallen KJ, Gnad-Vogt U, Zippelius A.

BMC Cancer. 2014 Oct 6;14:748. doi: 10.1186/1471-2407-14-748.


Compensatory mechanisms allow undersized anchor-deficient class I MHC ligands to mediate pathogenic autoreactive T cell responses.

Lamont D, Mukherjee G, Kumar PR, Samanta D, McPhee CG, Kay TW, Almo SC, DiLorenzo TP, Serreze DV.

J Immunol. 2014 Sep 1;193(5):2135-46. doi: 10.4049/jimmunol.1400997. Epub 2014 Jul 25.

Supplemental Content

Support Center